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Background
Hyperinsulinemia, hyperglycemia, and obesity have been
identified as risk factors for a variety of cancers [1]. Insulin
inhibition (INSINH) can potentially limit cancer growth by
factors including ketosis [2], and apoptosis secondary to
fatty acid synthase inhibition [3] as well as intracellular
potassium depletion [4]. Furthermore, dysregulation of
many signaling proteins downstream of the insulin/IGF
receptors such as PI3K/Akt, mTOR (inhibition) and AMPK
(amplification) is a major area of drug target development
[5,6]. We performed a four week INSINH diet in patients
with advanced cancers to study safety/feasibility and also to
examine a change in18F-2-fluoro, 2-deoxyglucose (FDG)
uptake on PET scan as a surrogate measure for tumor
response.
Methods
Eligible patients had failed or refused ≥2 standard che-
motherapy courses. Exclusions included concurrent che-
motherapy, end-organ disease, hypoglycemic medications,
difficult compliance, or BMI < 20. A supervised INSINH
diet restricted starches and sugars for 28 days, and was
monitored weekly for macronutrient intake, body weight,
[glucose] [BHB], [insulin], [IGF1,2]. An exit four-week
PET was obtained for comparison with the baseline scan.
Results
Ten subjects with diverse cancers completed ≥ 26 days of
INSINH without associated unsafe adverse effects. Mean
caloric intake decreased (35 ± 6) % vs. predicted require-
ments despite our best efforts to encourage increased food
consumption. Weight loss (median 4%, range 0.0-6.1%)
was not judged a health risk in any subject. Mild, reversi-
ble side effects included constipation (n=2), transient fati-
gue (n=5), and leg cramps (n=2). Among nine patients
with pre-trial progressive disease (PD) five demonstrated
post-trial stable disease or partial remission (SD/ PR) on
PET. SD/PR correlated with three-fold higher ketosis com-
pared to those with continued PD (n=4), (p<0.02), but was
uncorrelated with reduced calorie intake (p=0.45) or
weight loss (p=0.81). Insulin correlated inversely with
ketosis (r=0.62, p=0.026), but did not correlate with IFG
(1 or 2).
Conclusions
Preliminary pilot data in ten subjects demonstrated that an
INSINH diet is safe and feasible in selected patients with
advanced cancer. The extent of ketosis, but neither calorie
deficit nor weight loss correlated with SD/PR. The small
sample size requires further study. Further exploration is
also required to evaluate an insulin inhibiting diet’s:
1. mechanism in relation to calorie restriction; 2. role as an
adjunct to metabolic or cytotoxic therapies; 3. long-term
value to reduce overall cancer risk.
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